At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 15 target
Drug / intervention
Cryoablation Combined with Tirelizumab and Bevacizumabcombination
Likely dose
Cryoablation Combined with Tirelizumab and Bevacizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study of Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic Triple Negative Breast Cancer Patients Failed by Multiline Therapy
In Brief
A Phase 2 clinical trial evaluating Cryoablation Combined with Tirelizumab and Bevacizumab for Metastatic Breast Cancer in the Liver. Targeting 15 participants across 2 sites.
Detailed Summary
This is a Phase II, open-label study evaluating the efficacy and safety of Cryoablation combined with Tirelizumab and Bevacizumab in liver metastatic triple-negative breast cancer patients failed by multiline therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer in the Liver
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2023202420252026
First PostedMar 2022
Enrollment StartMay 2022
Primary CompletionApr 2024
TodayJul 2026
First PostedMar 31, 2022
Enrollment StartMay 1, 2022
Primary CompletionApr 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 4.3 years ago
Interventions
Cryoablation Combined with Tirelizumab and Bevacizumabcombination
Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles. 200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation.